Electronic Supplementary Material (ESI) for Analyst.

Supplementary Material

Potential of mid-infrared spectroscopy as a non-invasive diagnostic test for endometrial or ovarian cancer in urine

Maria Paraskevaidi[a,1], Camilo L.M. Morais[a,b], Kássio M.G. Lima[b], Katherine M. Ashton[c], Helen F. Stringfellow[c], Pierre L. Martin-Hirsch[d] and Francis L. Martin[a,1]

[a]School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK; [b]Institute of Chemistry, Biological Chemistry and Chemometrics, Federal University of Rio Grande do Norte, Natal 59072-970, Brazil; [c]Pathology Department, Lancashire Teaching Hospitals NHS Foundation, Preston PR2 9HT, UK; [d]Department of Obstetrics and Gynaecology, Lancashire Teaching Hospitals NHS Foundation, Preston PR2 9HT, UK

[1]To whom correspondence should be addressed. Email: mparaskevaidi@uclan.ac.uk or flmartin@uclan.ac.uk; Tel: +44 (0) 1772 89 6482



Supplementary Fig. 1: A) Raw spectra for all samples analysed (healthy, endometrial and ovarian cancer). (B) Average raw spectrum for healthy, endometrial and ovarian cancer groups.



Supplementary Fig. 2: Pre-processed spectra (A); Top six peaks that were found responsible for the discrimination between endometrial and ovarian cancer from healthy individuals (B).

Supplementary Table 1: Correct classification (%) of training and test set using PLS-DA, PCA-SVM and GA-LDA algorithms.

Algorithm	Training set (%)	Test set (%)
PLS-DA	85.0	72.5
PCA-SVM	97.2	95.8
GA-LDA	95.0	90.0

PLS-DA: Partial Least Squares-Discriminant Analysis; PCA-SVM: Principal Component Analysis-Support Vector Machines; GA-LDA: Genetic Algorithm-Linear Discriminant Analysis